Provided by our collaboration partner Agility Life Sciences, formulation development and pre-formulation checks can be seamlessly integrated into Inaphaea’s cell-based services, ensuring that your molecules is ready for Inaphaea’s cell-based assays; or using Inaphaea’s services to confirm your new formulation remains bioactive. Agility is an award-winning formulation development CDMO, focussed on accelerating your milestones and futureproofing your products. Futureproof your formulations, fast. We develop formulations to give badly behaved molecules the best chance of success in preclinical studies, and enable them to be accelerated to clinic or commercialisation. Our “Fast Futureproof Formulations” approach means that before we embark on a development project. Please visit https://agilitylifesciences.com/

We consider:

• The molecule: What are the properties of the molecule which we need to formulate around/out (for example, poor solubility and/or permeability)?
• The endgame: Where does the client want to take the product. e.g. GLP tox, Phase I, commercial? What is the target product profile?
• The imminent studies: What are the timelines, doses and route(s) of administration?
• Is the current formulation appropriate for Inaphaea’s cell-based assays?
• The species: What are the dosing volumes? What are the restrictions on format and/or excipients?

Overcoming obstacles with formulation development

Then, rather than conducting generic screens which waste time, money and precious API, we develop formulations to overcome the problematic properties of the molecule. We make sure that these products are fit for the current and future purpose. Our formulations specialisms include oral, ocular, intravenous, intranasal, topical and subcutaneous products. We develop and manufacture formulations to meet the needs of our clients including:

• Overcoming solubility and permeability issues.
• Immediate, controlled and sustained release.
• Formulations and analytical methods suitable for preclinical safety and efficacy studies, including GLP tox studies.
• Clinical and commercial prototypes.
• Reverse engineering of existing products.

Talk directly to your Inaphaea representative about how Agility’s capabilities can enhance your projects and we will ensure the right skills and experience are brought into the conversation. Click here to contact us.